Author:
Shintani Takashi,Anami Shimpei,Sano Keisuke,Okada Wataru,Tanooka Masao
Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer;Kishan AU;JAMA Netw Open,2019
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial;Widmark A;Lancet,2019
3. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial;Brand DH;Lancet Oncol,2019
4. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial;Tree AC;Lancet Oncol,2022
5. NCCN guideline. (2023). Accessed. April 19, 2023: https://www.nccn.org/guidelines/nccn-guidelines.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献